2023
Perspectives on contingency management for alcohol use and alcohol‐associated conditions among people in care with HIV
Cohen S, DePhilippis D, Deng Y, Dziura J, Ferguson T, Fucito L, Justice A, Maisto S, Marconi V, Molina P, Paris M, Rodriguez‐Barradas M, Simberkoff M, Petry N, Fiellin D, Edelman E. Perspectives on contingency management for alcohol use and alcohol‐associated conditions among people in care with HIV. Alcohol Clinical And Experimental Research 2023, 47: 1783-1797. PMID: 37524371, PMCID: PMC10828101, DOI: 10.1111/acer.15159.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol useContingency managementPrimary care settingSubset of participantsReward structureEvidence-based approachHIV clinicImplementation science frameworkTreatment trialsClinical trialsIntervention feasibilityCare settingsPromoting ActionAlcohol consumptionRelated conditionsBiochemical testingClinical contextHIVReward schedulePatientsReward processesInterventionTrialsBehavior change
2021
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin H, Posner DC, Ho YL, Rentsch CT, Tate JP, King JT, Kurgansky KE, Danciu I, Costa L, Linares FA, Goethert ID, Jacobson DA, Freiberg MS, Begoli E, Muralidhar S, Ramoni RB, Tourassi G, Gaziano JM, Justice AC, Gagnon DR, Cho K. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. American Journal Of Epidemiology 2021, 190: 2405-2419. PMID: 34165150, PMCID: PMC8384407, DOI: 10.1093/aje/kwab183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsAzithromycinCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisMachine LearningMaleMiddle AgedPharmacoepidemiologyRetrospective StudiesSARS-CoV-2Treatment OutcomeUnited StatesVeteransConceptsUS veteransCOVID-19Veterans Affairs Health Care SystemRecent randomized clinical trialsAdministration of hydroxychloroquineEffectiveness of hydroxychloroquineRisk of intubationEffect of hydroxychloroquineElectronic health record dataRandomized clinical trialsTreatment of patientsUS veteran populationCOVID-19 outcomesCoronavirus disease 2019Health record dataRigorous study designsHealth care systemSurvival benefitTreat analysisEarly therapyHospitalized populationClinical trialsObservational studyDisease 2019Hydroxychloroquine
2020
Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV
Eyawo O, Deng Y, Dziura J, Justice AC, McGinnis K, Tate JP, Rodriguez‐Barradas M, Hansen NB, Maisto SA, Marconi VC, O’Connor P, Bryant K, Fiellin DA, Edelman EJ. Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV. Alcohol Clinical And Experimental Research 2020, 44: 2053-2063. PMID: 33460225, PMCID: PMC8856627, DOI: 10.1111/acer.14435.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useSignificant alcohol useHeavy drinking daysAlcohol use disorderTimeline FollowbackAlcohol useSelf-reported alcohol useNumber of drinksClinical trialsRisk drinkingUse disordersDrinking daysBiomarker-based evidenceSample of PWHDrinks/dayMean numberSelf-reported alcohol consumptionMagnitude of associationBlood spot samplesLiver diseasePEth levelsTLFB interviewAlcohol consumptionLogistic regressionPatients
2019
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2015
Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trials
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir
2011
Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya
Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, Songole R, Omolo OE, Kamanda AM, Ayuku DO, Ojwang C, Owino‐Ong'or W, Harrington M, Bryant KJ, Carroll KM, Justice AC, Hogan JW, Maisto SA. Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya. Addiction 2011, 106: 2156-2166. PMID: 21631622, PMCID: PMC3208780, DOI: 10.1111/j.1360-0443.2011.03518.x.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAlcohol useDrinking daysLarge human immunodeficiency virusCognitive behavioral therapy interventionAlcohol intervention studyAlcohol use disorderGroup Cognitive Behavioral Therapy InterventionEffect sizeTreatment effect sizeCognitive behavioral therapyDual epidemicsRandomized participantsPatient clinicImmunodeficiency virusPreliminary efficacyHuman immunodeficiencyClinical trialsTreatment outcomesAlcohol abstinenceAssessment-only controlBinge drinkingUse disordersTherapy interventionFeasible intervention
2008
Determinants of Hormone Therapy Discontinuation among Female Veterans Nationally
Haskell SG, Bean-Mayberry B, Goulet JL, Skanderson M, Good CB, Justice AC. Determinants of Hormone Therapy Discontinuation among Female Veterans Nationally. Military Medicine 2008, 173: 91-96. PMID: 18251338, PMCID: PMC3115618, DOI: 10.7205/milmed.173.1.91.Peer-Reviewed Original ResearchConceptsVA women's clinicsHormone therapyHealth care servicesFemale veteransWomen's clinicWomen's Health Initiative clinical trialsVeterans Affairs Health Care SystemUse of HTWomen's health care servicesVA systemGender-specific careAfrican American raceHormone therapy discontinuationHealth care systemHT discontinuationHT GuidelineTherapy discontinuationDiscontinuation ratesHT useClinical trialsHeart diseaseHispanic ethnicityVA pharmacyAmerican raceCare services